Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2017, Article ID 2906282, 12 pages
https://doi.org/10.1155/2017/2906282
Research Article

Periodically Pulsed Immunotherapy in a Mathematical Model of Tumor, CD4+ T Cells, and Antitumor Cytokine Interactions

1Department of Applied Mathematics, Feng Chia University, Seatwen, Taichung 40724, Taiwan
2Department of Financial and Computational Mathematics, Providence University, Shalu Dist., Taichung 43301, Taiwan

Correspondence should be addressed to Jui-Ling Yu; wt.ude.up.mg@uylj

Received 11 June 2017; Revised 15 September 2017; Accepted 12 October 2017; Published 9 November 2017

Academic Editor: Konstantin Blyuss

Copyright © 2017 Hsiu-Chuan Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. SkinCancerFundation, “What is melanoma?” 2016, http://www.skincancer.org/skin-cancer-information/melanoma.
  2. MedicineNet.com, Melanoma introduction, 1996, http://www.medicinenet.com/script/main/art.asp?articlekey=20093page=9.
  3. E. Bastiaannet, J. C. Beukema, and H. J. Hoekstra, “Radiation therapy following lymph node dissection in melanoma patients: Treatment, outcome and complications,” Cancer Treatment Reviews, vol. 31, no. 1, pp. 18–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. K. Shakir and K. I. Rasul, “Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management,” Journal of Clinical Medicine Research, vol. 1, no. 1, pp. 8–12, 2009. View at Publisher · View at Google Scholar
  5. S. A. Rosenberg and N. P. Restifo, “Adoptive cell transfer as personalized immunotherapy for human cancer,” Science, vol. 348, no. 6230, pp. 62–68, 2015. View at Publisher · View at Google Scholar
  6. S. Van Lint, S. Wilgenhof, C. Heirman et al., “Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula,” Cancer Immunology, Immunotherapy, vol. 63, no. 9, pp. 959–967, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. S. R. M. Bennett, F. R. Carbone, F. Karamalis, J. F. A. P. Miller, and W. R. Heath, “Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help,” The Journal of Experimental Medicine, vol. 186, no. 1, pp. 65–70, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Hung, R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky, “The central role of CD4+ T cells in the antitumor immune response,” The Journal of Experimental Medicine, vol. 188, no. 12, pp. 2357–2368, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Mattes, M. Hulett, W. Xie et al., “Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process,” The Journal of Experimental Medicine, vol. 197, no. 3, pp. 387–393, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Zhang, D. Bernard, W. I. Khan, M. H. Kaplan, J. L. Bramson, and Y. Wan, “CD4+ T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis,” European Journal of Immunology, vol. 39, no. 5, pp. 1252–1259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Xie, A. Akpinarli, C. Maris et al., “Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma,” The Journal of Experimental Medicine, vol. 207, no. 3, pp. 651–667, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Perez-Diez, N. T. Joncker, K. Choi et al., “CD4 cells can be more efficient at tumor rejection than CD8 cells,” Blood, vol. 109, no. 12, pp. 5346–5354, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Eftimie, J. L. Bramson, and D. J. Earn, “Interactions between the immune system and cancer: a brief review of non-spatial mathematical models,” Bulletin of Mathematical Biology, vol. 73, no. 1, pp. 2–32, 2011. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  14. R. Eftimie, J. L. Bramson, and D. J. Earn, “Modeling anti-tumor Th1 and TH2 immunity in the rejection of melanoma,” Journal of Theoretical Biology, vol. 265, no. 3, pp. 467–480, 2010. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  15. L. Anderson, S. Jang, and J.-L. Yu, “Qualitative behavior of systems of tumor CD4+ cytokine interactions with treatments,” Mathematical Methods in the Applied Sciences, vol. 38, no. 17, pp. 4330–4344, 2015. View at Publisher · View at Google Scholar · View at MathSciNet
  16. D. Kirschner and J. C. Panetta, “Modeling immunotherapy of the tumo—immune interaction,” Journal of Mathematical Biology, vol. 37, no. 3, pp. 235–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor, and A. S. Perelson, “Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis,” Bulletin of Mathematical Biology, vol. 56, no. 2, pp. 295–321, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. H. P. de Vladar and J. A. González, “Dynamic response of cancer under the influence of immunological activity and therapy,” Journal of Theoretical Biology, vol. 227, no. 3, pp. 335–348, 2004. View at Publisher · View at Google Scholar · View at MathSciNet
  19. Y. A. Kuznetsov, Elements of Applied Bifurcation Theory, Springer, Berlin, Germany, 2nd edition, 1997. View at MathSciNet
  20. H.-C. Wei and J.-T. Lin, “Periodically pulsed immunotherapy in a mathematical model of tumor-immune interaction,” International Journal of Bifurcation and Chaos, vol. 23, no. 4, 1350068, 13 pages, 2013. View at Google Scholar · View at MathSciNet
  21. H.-C. Wei, “A modified numerical method for bifurcations of fixed points of ODE systems with periodically pulsed inputs,” Applied Mathematics and Computation, vol. 236, pp. 373–383, 2014. View at Publisher · View at Google Scholar · View at MathSciNet
  22. O. V. Volpert, T. Fong, A. E. Koch et al., “Inhibition of angiogenesis by interleukin 4,” The Journal of Experimental Medicine, vol. 188, no. 6, pp. 1039–1046, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. E. C. Hsueh, E. Famatiga, S. Shu, X. Ye, and D. L. Morton, “Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma,” Annals of Surgical Oncology, vol. 11, no. 10, pp. 892–899, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. E. H. Slager, M. Borghi, C. E. Van der Minne et al., “CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: A tumor antigen translated in an alternative open reading frame,” The Journal of Immunology, vol. 170, no. 3, pp. 1490–1497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. M. B. Atkins, “Immunotherapy and experimental approaches for metastatic melanoma,” Hematology/Oncology Clinics of North America, vol. 12, no. 4, pp. 877–902, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. F. O. Nestle, S. Alijagic, M. Gilliet et al., “Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells,” Nature Medicine, vol. 4, no. 3, pp. 328–332, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Okada, F. S. Lieberman, K. A. Walter et al., “Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas,” Journal of Translational Medicine, vol. 5, article no. 67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Okada, L. Villa, J. Attanucci et al., “Cytokine gene therapy of gliomas: Effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells,” Gene Therapy, vol. 8, no. 15, pp. 1157–1166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Kronik, Y. Kogan, P. G. Schlegel, and M. Wölfl, “Improving T-cell immunotherapy for melanoma through a mathematically motivated strategy: efficacy in numbers?” Journal of Immunotherapy, vol. 35, no. 2, pp. 116–124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Plesnicar, G. Klanjscek, and S. Modic, “Actual doubling time values of pulmonary metastases from malignant melanoma,” ANZ Journal of Surgery, vol. 48, no. 1, pp. 23–25, 1978. View at Publisher · View at Google Scholar · View at Scopus
  31. P. J. Conlon, S. Tyler, K. H. Grabstein, and P. Morrissey, “Interleukin-4 (B-cell stimulatory factor-1) augments the in vivo generation of cytotoxic cells in immunosuppressed animals,” Biotechnology Therapeutics, vol. 1, no. 1, pp. 31–41, 1989. View at Google Scholar · View at Scopus
  32. C. Yee, J. A. Thompson, and D. Byrd, “Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 99, no. 25, pp. 16168–16173, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. M. E. Dudley, J. R. Wunderlich, P. F. Robbins et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850–854, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. G. E. Plautz, R. M. Bukowski, A. C. Novick et al., “T-cell adoptive immunotherapy of metastatic renal cell carcinoma,” Urology, vol. 54, no. 4, pp. 617–624, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. Wikipedia, Whitebloodcell, 2016, http://en.wikipedia.org/wiki/White.
  36. M. K. Callahan, J. D. Wolchok, and J. P. Allison, “AntiCTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy,” Seminars in Oncology, vol. 37, no. 5, pp. 473–484, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. A. Quezada, T. R. Simpson, and K. S. Peggs, “Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts,” The Journal of Experimental Medicine, vol. 207, no. 3, pp. 637–650, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Shklovskaya, A. M. Terry, T. V. Guy et al., “Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen,” Immunology & Cell Biology, vol. 94, no. 6, pp. 593–603, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Snyder, V. Makarov, and T. Merghoub, “Genetic basis for clinical response to CTLA-4 blockade in melanoma,” The New England Journal of Medicine, vol. 371, pp. 2189–2199, 2014. View at Publisher · View at Google Scholar
  40. J. D. Wolchok and Y. Saenger, “The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.,” The Oncologist, vol. 13, pp. 2–9, 2008. View at Publisher · View at Google Scholar · View at Scopus